Literature DB >> 2856708

Cardiovascular responses to verapamil and propranolol in hypertensive patients.

G T McInnes1, I N Findlay, G Murray, J G Cleland, H J Dargie.   

Abstract

Since there is concern that the potentially useful antihypertensive combination of verapamil and propranolol might lead to adverse cardiovascular responses, we have investigated its effects, not only on blood pressure, but also on electrocardiographic and echocardiographic variables. Fourteen hypertensive patients participated in a double-blind, randomized, crossover comparison of verapamil 360 mg, propranolol 240 mg, verapamil 360 mg + propranolol 240 mg, and placebo, each given for 4 weeks. The antihypertensive effect of verapamil + propranolol was greater than that of either drug alone. Pulse rate was reduced by propranolol but not verapamil. However, addition of verapamil to propranolol led to further reduction in pulse rate. The PR interval was prolonged by verapamil + propranolol when compared with all other treatments. The active drugs increased ventricular dimensions and the effect of the combination was statistically significant. Thus, verapamil + propranolol is an effective antihypertensive combination, but heart rate, atrio-ventricular conduction and left ventricular function may be affected adversely, necessitating careful monitoring of therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2856708

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  4 in total

1.  Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.

Authors:  D L Murdoch; G D Thomson; G G Thompson; G D Murray; M J Brodie; G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 2.  Drug interactions that matter. A critical reappraisal.

Authors:  G T McInnes; M J Brodie
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 3.  Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

Review 4.  Combination therapy with beta-adrenoceptor blockers and calcium antagonists.

Authors:  H J Dargie
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.